Magali Olivier

List of Publications by Year
in descending order

80 papers	11,086 citations	81839 39 h-index	91828 69 g-index
90 all docs	90 docs citations	90 times ranked	16721 citing authors

#	Article	IF	Citations
1	TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001008-a001008.	2.3	1,494
2	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation, 2007, 28, 622-629.	1.1	1,441
3	The IARC TP53 database: New online mutation analysis and recommendations to users. Human Mutation, 2002, 19, 607-614.	1.1	1,107
4	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 2002, 21, 7435-7451.	2.6	961
5	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 2007, 26, 2157-2165.	2.6	796
6	*TP53* Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Human Mutation, 2016, 37, 865-876.	1.1	589
7	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. Clinical Cancer Research, 2006, 12, 1157-1167.	3.2	495
8	Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 2003, 63, 6643-50.	0.4	350
9	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Research, 2006, 34, 1317-1325.	6.5	295
10	Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002. Clinical Cancer Research, 2014, 20, 4613-4624.	3.2	195
11	Sarcomas in *TP53* germline mutation carriers. Cancer, 2012, 118, 1387-1396.	2.0	189
12	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death and Differentiation, 2011, 18, 1815-1824.	5.0	173
13	The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 2007, 245, 96-102.	3.2	170
14	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine, 2016, 10, 117-123.	2.7	153
15	Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Therapy, 2011, 18, 2-11.	2.2	151
16	Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Therapy, 2009, 16, 1-12.	2.2	140
17	Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Human Mutation, 2002, 19, 149-164.	1.1	122
18	Detailed haplotype analysis at the *TP53* locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Human Mutation, 2010, 31, 143-150.	1.1	116

#	Article	IF	Citations
19	Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. European Respiratory Journal, 2015, 46, 1773-1780.	3.1	114
20	Modulation of DNA Topoisomerase I Activity by p53. Biochemistry, 1996, 35, 5778-5786.	1.2	99
21	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Letters, 2008, 261, 21-25.	3.2	94
22	Prognostic value of *TP53*, *KRAS* and *EGFR* mutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 2012, 40, 177-184.	3.1	92
23	Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Current Opinion in Oncology, 2010, 22, 64-69.	1.1	91
24	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research, 2017, 27, 1475-1486.	2.4	90
25	Biomarkers Predict *p53* Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2009, 15, 7719-7725.	3.2	87
26	Modelling mutational landscapes of human cancers in vitro. Scientific Reports, 2014, 4, 4482.	1.6	83
27	TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. Iarc (international Agency for Research on Cancer) Scientific Publications, 2004, , 247-70.	0.4	83
28	Specifications of the ACMG/AMP variant interpretation guidelines for germline *TP53* variants. Human Mutation, 2021, 42, 223-236.	1.1	81
29	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. Journal of Medical Genetics, 2009, 46, 766-772.	1.5	64
30	p53 regulates the transcription of its Î"133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene, 2010, 29, 2691-2700.	2.6	60
31	Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. Genome Research, 2019, 29, 521-531.	2.4	57
32	TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Seminars in Cancer Biology, 2001, 11, 353-360.	4.3	56
33	Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutation Research - Reviews in Mutation Research, 2013, 753, 41-49.	2.4	55
34	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death and Differentiation, 2022, 29, 1071-1073.	5.0	53
35	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research, 2012, 14, R70.	2.2	52
36	Differential Activation of p53 by the Various Adducts of Mitomycin C. Journal of Biological Chemistry, 2002, 277, 40513-40519.	1.6	50

#	Article	IF	Citations
37	TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis, 2001, 16, 551-553.	1.0	47
38	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinoma. Human Mutation, 2004, 24, 21-34.	1.1	46
39	MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes. BMC Bioinformatics, 2016, 17, 170.	1.2	44
40	A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death and Disease, 2013, 4, e492-e492.	2.7	43
41	Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Human Mutation, 2008, 29, 1273-1281.	1.1	41
42	Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Current Opinion in Oncology, 2011, 23, 88-92.	1.1	41
43	TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report. BMC Cancer, 2011, 11, 449.	1.1	34
44	The International Collaboration for Cancer Classification and Research. International Journal of Cancer, 2021, 148, 560-571.	2.3	32
45	The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 551-583.	2.7	31
46	p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. International Journal of Cancer, 2011, 128, 1813-1821.	2.3	29
47	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis, 2014, 35, 807-815.	1.3	29
48	Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by <i>TP53</i> variants. Human Mutation, 2018, 39, 1061-1069.	1.1	29
49	Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Research and Treatment, 2011, 125, 35-42.	1.1	27
50	p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Letters, 2011, 300, 215-224.	3.2	25
51	Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-typep53. Molecular Carcinogenesis, 1998, 23, 1-12.	1.3	23
52	Low Prevalence of<i>TP53</i>Mutations and<i>MDM2</i>Amplifications in Pediatric Rhabdomyosarcoma. Sarcoma, 2012, 2012, 1-6.	0.7	23
53	Upper urinary tract urothelial cancers: where it is A:T. Nature Reviews Cancer, 2012, 12, 503-504.	12.8	22
54	Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Human Mutation, 2006, 27, 163-172.	1.1	21

#	Article	IF	Citations
55	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1873-1881.	1.1	21
56	A quantitative model to predict pathogenicity of missense variants in the *TP53* gene. Human Mutation, 2019, 40, 788-800.	1.1	21
57	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. PLoS ONE, 2015, 10, e0126762.	1.1	18
58	TP53 mutations as biomarkers for cancer epidemiology in Latin America: Current knowledge and perspectives. Mutation Research - Reviews in Mutation Research, 2005, 589, 192-207.	2.4	16
59	Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: Proposed guidelines for improving data collection, distribution, and integration. Human Mutation, 2009, 30, 275-282.	1.1	14
60	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		13
61	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS ONE, 2019, 14, e0210372.	1.1	12
62	Anthropometry, body shape in early-life and risk of premenopausal breast cancer among Latin American women: results from the PRECAMA study. Scientific Reports, 2020, 10, 2294.	1.6	10
63	Project profile: a multicenter study on breast cancer in young women in Latin America (PRECAMA) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	7
64	Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. International Journal of Cancer, 2022, 150, 374-386.	2.3	4
65	Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		4
66	TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers. , 2013, , 127-146.		2
67	PVAmpliconFinder: a workflow for the identification of human papillomaviruses from high-throughput amplicon sequencing. BMC Bioinformatics, 2020, 21, 233.	1.2	2
68	Response to â€œGermline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndromeâ€‚ by Ribeiro et al.. Cancer Letters, 2007, 247, 356-358.	3.2	1
69	TP53 Mutations in Human Cancers: Selection versus Mutagenesis. Molecular Biology Intelligence Unit, 2010, , 1-18.	0.2	1
70	Assessing TP53 Status in Human Tumors: Lessons from Breast Cancer. , 2013, , 147-165.		1
71	IARC TP53 Database. , 2011, , 1799-1802.		1
72	Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients. Breast Cancer Research, 2005, 7, 1.	2.2	0

#	Article	IF	Citations
73	Influence of TP53 gene status on treatment response in breast cancer cells. European Journal of Cancer, Supplement, 2008, 6, 104.	2.2	0
74	MA11.05 A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls. Journal of Thoracic Oncology, 2017, 12, S405-S406.	0.5	0
75	Abstract 5538: Sarcomas in TP53 germline mutation carriers. , 2011, , .		0
76	Abstract 305: Ultra-low coverage exome sequencing of FFPE tumor specimens identifies exposure to carcinogenic aristolochic acid. , 2014, , .		0
77	Abstract 4748: Revealing the molecular portrait of triple negative breast tumors from an understudied population through omics analysis of formalin-fixed and paraffin-embedded tissues. , 2015, , .		0
78	IARC TP53 Database. , 2017, , 2193-2198.		0
79	Patterns of TP53 Mutations in Human Cancer: Interplay between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		0
80	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		0